Lenvatinib

Lenvatinib

CAT N°: 19375
Price:

From 48.00 40.80

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively).{32663,32664} It also inhibits the related kinases VEGFR1, FGFR1, PDGFR?, PDGFR? and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively).{32663} Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

We also advise you

TAF 10 Peptide

TAF 10 Peptide

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity.{16903} One vial of this peptide...

€191.00
View